Narmac, DND I have to say I agree with you here. As narmac said share price is the responsibility of the CEO, miserable failure in that respect.  I have similar recollections as DND when it comes to CEO comments regarding BETONMACE funding requirements and as a shareholder I take no joy in expressing my concerns about corporate performance.  

IMO there is a significant and growing amount of extrordinary science within RVX. Great cutting edge science in an area of significant unmet need is why I am invested in RVX.  Poor corporate performance is why I have scaled back my financial commitment to RVX by selling shares and replacing them with warrants.  The misguided BB financing last year when warrants were trading at 3:1 to shares was a great time to take money off the table. I was deeply disappointed when recently management announced they were going to repeat that mistake again. Hopefully sober second thought prevails but the short damage to the share price has already occurred. Management gaffes resulting in share price erosion make it hard to build on the share price when the market is trained to expect a better entry point down the road.

I firmly believe that RVX would be a $10 to $15 stock (with somewhat less dilution) if company business was well run by a CEO with a track record of accomplishment in Biotech who had delivered on the company program as promised.  The $10 to $15 ballpark estimate is from applying EV/market cap ratios across a number of similar stage biotech’s and using management’s past EV chart.  If the company was adequately funded with unencumbered IP and well underway on the CKD/hemodialysis trial, Fabry’s trial and just one of the other six or seven other clinic ready compounds we would likely be looking at a vastly better stock price that better reflected the value of the science. Investors would be able to see a clear path to a funded future with multiple opportunities. Additionally, if the aforementioned as promised program had been delivered upon RVX would have a much better risk reward profile as relatively less would be riding on top line BETOnMACE.

As a shareholder the underwhelming corporate performance is deeply disappointing and, I think, worthy of discussion.